Core Viewpoint - The article discusses the announcement of a project by Ningxia Zhongke Biological New Materials Co., Ltd. to produce 110,900 tons of bio-fermentation products annually, highlighting the company's technological upgrades and production capabilities in the bio-manufacturing sector [1]. Project Overview - Project Name: Annual production of 110,900 tons of bio-fermentation products - Construction Unit: Ningxia Zhongke Biological New Materials Co., Ltd. - Nature of Construction: Technological upgrade - Industry Category: C2710 Chemical raw materials and pharmaceutical manufacturing - Investment: 100.89 million yuan - Location: Shizuishan Economic and Technological Development Zone - Land Area: 387,309.18 m², utilizing existing facilities without new land acquisition [2]. Construction Scale - The project includes four flexible production lines: 1. Long-chain dicarboxylic acid production line: Annual capacity of 18,000 tons, producing various dicarboxylic acids [3]. 2. Bio-fermentation functional products production line: Annual capacity of 5,100 tons, including D-chiro-inositol, coenzyme Q10, and DHA algae oil [4]. 3. Bio-food production line: Annual capacity of 63,000 tons, producing calcium propionate and L-malic acid [5]. 4. Amino acid products production line: Annual capacity of 24,800 tons, producing various amino acids [6]. Technological Upgrade Scope - The upgrade encompasses fermentation workshops, extraction workshops, refining workshops, drying workshops, liquid bio-fertilizer workshops, tank areas, and power centers [7]. Company Background - Ningxia Zhongke Biological New Materials Co., Ltd. was established on June 2, 2017, with a registered capital of 1.3 billion yuan. The company is involved in the production of feed additives, food additives, fertilizers, and bio-based materials [8]. Financial Performance - The company reported revenue of 345 million yuan and a net loss of 539 million yuan during the reporting period. To address its debt crisis, the company entered pre-restructuring in May 2024, with government support extended until the end of 2024 [9]. - In the first quarter of 2025, the company achieved total revenue of 93.82 million yuan, a year-on-year increase of 74.08%, but still reported a net loss of 64.08 million yuan [11].
1个亿,力挽狂澜?ST宁科拟实施年产11.09万吨生物发酵产品技改项目,布局长链二元酸、氨基酸等
合成生物学与绿色生物制造·2025-06-24 08:25